Finanzen von Upstream Bio Inc (UPB)UPBUpstream Bio Inc

Evaluating the bottom line, Upstream Bio, Inc. maintains a gross margin of 100.00%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -5480.98%, while the net margin is -5136.09%. These profitability ratios, combined with a Return on Equity (ROE) of -46.05%, provide a clear picture of how effectively UPB converts its operational activities into shareholder value.

In the context of the broader market, UPB competes directly with industry leaders such as CGEN and ZNTL. With a market capitalization of $202.65M, it holds a leading position in the sector. When comparing efficiency, UPB's gross margin of 100.00% stands against CGEN's -3.54% and ZNTL's N/A. Such benchmarking helps identify whether Upstream Bio, Inc. is trading at a premium or discount relative to its financial performance.

Upstream Bio has shown fluctuating revenues, with Q1 2026 revenue at $1.034 million but a net loss of $40.59 million. The gross margin remains high at 100%, but the overall financial health is concerning due to ongoing losses.